GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Median PS Value

Heidelberg Pharma AG (XTER:HPHA) Median PS Value : €2.91 (As of May. 25, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Heidelberg Pharma AG's Revenue per Share for the trailing twelve months (TTM) ended in Feb. 2024 was €0.195. Heidelberg Pharma AG's 10-Year median PS Ratio is 14.9231. Therefore, the Median PS Value for today is €2.91.

As of today (2024-05-25), Heidelberg Pharma AG's share price is €2.94. Heidelberg Pharma AG's Median PS Value is €2.91. Therefore, Heidelberg Pharma AG's Price to Median PS Value for today is 1.01.

The historical rank and industry rank for Heidelberg Pharma AG's Median PS Value or its related term are showing as below:

XTER:HPHA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.67   Med: 1.32   Max: 10.69
Current: 1.01

During the past 13 years, the highest Price to Median PS Value of Heidelberg Pharma AG was 10.69. The lowest was 0.67. And the median was 1.32.

XTER:HPHA's Price-to-Median-PS-Value is ranked worse than
66.67% of 261 companies
in the Biotechnology industry
Industry Median: 0.68 vs XTER:HPHA: 1.01

Heidelberg Pharma AG Median PS Value Historical Data

The historical data trend for Heidelberg Pharma AG's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG Median PS Value Chart

Heidelberg Pharma AG Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.88 2.51 0.51 6.96 3.13

Heidelberg Pharma AG Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.27 3.44 2.86 3.13 2.91

Competitive Comparison of Heidelberg Pharma AG's Median PS Value

For the Biotechnology subindustry, Heidelberg Pharma AG's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heidelberg Pharma AG's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Heidelberg Pharma AG's Price-to-Median-PS-Value falls into.



Heidelberg Pharma AG Median PS Value Calculation

Heidelberg Pharma AG's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0.195*14.9231
=2.91

10-Year Median PS Ratio is 14.9231.
Heidelberg Pharma AG's Revenue per Share for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.195.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Heidelberg Pharma AG  (XTER:HPHA) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Heidelberg Pharma AG's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=2.94/2.91
=1.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Heidelberg Pharma AG Median PS Value Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Heidelberg Pharma AG (XTER:HPHA) Business Description

Traded in Other Exchanges
Address
Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.
Executives
Prof. Dr. Andreas Pahl Board of Directors

Heidelberg Pharma AG (XTER:HPHA) Headlines

No Headlines